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Abstract
Background: Survival rate for patients presenting muscle invasive bladder cancer is very low, and useful
therapeutic target has not been identified yet. In the present study, new COX2 downstream signals involved in
urothelial carcinoma cell survival were investigated in vitro and in vivo.
Methods: COX2 gene was silenced by siRNA transfection. Orthotopic implantation animal model and transurethral
instillation of siRNA with atelocollagen was constructed to examine the effects of COX2 knockdown in vivo. Cell
cycle was examined by flowcytoketry. Surgical specimens derived from patients with urinary bladder cancer (all
were initially diagnosed cases) were used for immunohistochemical analysis of the indicated protein expression in
urothelial carcinoma cells.
Results: Treatment with the COX2 inhibitor or knockdown of COX2 reduced expression of casein kinase (CK) 2 a,a
phophorylated Akt and urokinase type plasminogen activator (uPA), resulting in p27 induction, cell cycle arrest at
G1 phase and cell growth suppression in human urothelial carcinoma cell lines expressing COX2. Silencing of CK2a
exhibited the similar effects. Even in UMUC3 cells lacking the COX2 gene, COX2 inhibition also inhibited cell
growth through down-regulation of the CK2a-Akt/uPA axis. The mouse orthotropic bladder cancer model
demonstrated that the COX2 inhibitor, meloxicam significantly reduced CK2a, phosphorylated Akt and uPA
expression, whereas induced p27 by which growth and invasiveness of bladder cancer cells were strongly
inhibited. Immunohistochemically, high expression of COX2, CK2a and phosphorylated form of Akt was found in
high-grade, invasive carcinomas as well as carcinoma in situ, but not in low-grade and noninvasive phenotypes.
Conclusions: COX2-dependent and independent activation of CK2a-Akt/uPA signal is mainly involved in urothelial
carcinoma cell survival, moreover, not only COX2 but also CK2a could be direct targets of COX2 inhibitors.
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Background
Cyclooxygenase (COX) 2 is an inducible enzyme that
produces prostaglandins during inflammatory and
tumorigenic processes[1]. The biology of COX2 in rela-
tion to tumor genesis has been well studied, particularly
with regard to colorectal cancer development. Aberrant
expression of COX2 as well as deregulation of WNT/b-
catenin signaling occurs in the majority of colorectal
tumor[2,3]. Deregulation of COX-2 expression leads to
an increased abundance of eicosanoids that affect the
hallmarks of cancer. For examples, COX2/prostaglandin
E2 signal is thought to protect tumor cells or tumor
initiating cells from apoptosis induction by regulating
pro- and/or anti-apoptotic molecules[4,5]. In contrast,
studies using in vivo animal models clearly indicated
over expression or over activation of COX2 only cannot
develop tumors spontaneously: breast cancer or colon
cancer cannot be induced in COX2 transgenic mice
without a murine mammary tumor virus infection or
azoxymethane treatment[6,7]. Thus, COX2 may be asso-
ciated with promotion, but not initiation, of several
types of human cancer.
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industrialized countries including Japan. More than 90%
of bladder cancer originates in the urothelial (transi-
tional) cells[8]. Low grade urothelial carcinoma can be
usually controlled by intravesical therapy; in contrast,
high grade cancer is much difficult to treat. Therefore,
identification of target molecules or signals involved in
urothelial carcinoma with high malignant potential is
needed for successful therapy. COX2 is well known to
enhance malignant potential of urothelial carcinoma
cells[9,10], and several types of COX2 inhibitors are
clinically used for not only treatment but also preven-
tion of bladder cancer[11]. However, COX2-mediated
signals involved in urothelial carcinoma cell survival
remain fully undetermined, in addition, the fact that
COX2 inhibitors have both COX2 -dependent and
-independent cytotoxic effects make us much difficult to
understand the biological roles. Casein kinase (CK) 2 is
a ubiquitous serine/threonine protein kinase, and its
heterotetrameric structure consists of two catalytic sub-
units (~42 kDa aand 38 kDa a’) and two regulatory
subunits (~28 kDa b)i na2b2, aa’b2, or a’2b2c o n f i g -
urations[12]. Recent reports demonstrated CK2 is clo-
sely associated with tumor progression by
phosphorylating a number of kinases [13,14]. CK2 is
widely expressed in various types of malignant tumors
[14,15], and many investigators have focused on CK2 as
a therapeutic target. Wang H. et al. showed CK2 down-
regulation induced apoptosis in prostate cancer cells
that may lead to novel cancer therapies[16]. However,
there are no available data on the clinicopathological
significance of CK2a in bladder cancer. In the present
study, we found that COX2 is an upstream molecule of
CK2a leading to Akt activation and urokinase type of
plasminogen activator (uPA) induction. Silencing or
inhibition of COX2 successfully inhibits CK2a-Akt/uPA
axis, resulting in cell cycle arrest and growth suppres-
sion of bladder cancer cells in vitro and in vivo. Interest-
ingly, even in urothelial carcinoma cells lacking COX2
gene, COX2 inhibitors reduced expression of CK2a and
cell viability. The data suggest both COX2 dependent
and independent activation of CK2a-Akt/uPA-mediated
promotion and such signals could be targeted by COX2
inhibitors in human bladder cancer.
Methods
Bladder cancer cell lines, chemicals and antibodies
Human urothelial carcinoma cell lines UMUC2 and
UMUC3 were cultured in RPMI supplemented with 10%
fetal bovine serum. The origins of UMUC2 and UMUC3
are urethral tumor (carcinoma in situ)a n db l a d d e r
tumor (invaded carcinoma), respectively. Wild type of
p53 is observed in UMUC2 cells, but it is largely deleted
in UMUC3 cells[17]. KU7 was derived from human
papillary bladder cancer[18]. We generated stable green
fluorescent protein (GFP) KU-7 cells as previously
described[19,20]. Antibodies to COX2, p27, Akt and
phosphorylated form Akt were purchased from Cell Sig-
naling (Boston, MA, USA); Antibodies to actin and
COX1 were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA); Antibodies to CK2a were supplied by
Abcam (Cambridge, UK). COX2 selective inhibitor,
CAY10404 or DuP-697 was from Cayman (Ann Arbor,
USA). Phosphatidylinositol-3-kinase inhibitor,
LY294002, soluble in DMSO was purchased from Cell
Signaling Technology Japan (Tokyo, Japan).
Preparation of cell lysates and Western blotting analysis
Cell lysates were resolved in SDS-polyacrylamide gels
and transferred onto polyvinylidene difluoride mem-
branes (Millipore, Ltd., MA, USA), which were then
blocked in 5% skim milk at room temperature for 1 h.
Membranes were incubated with the indicated primary
antibody (1:50-1000 dilution according to the manufac-
ture’s protocol) for 1 h, and then incubated with horse-
radish peroxidase-conjugated antimouse or antirabbit
IgG (1:5000 dilution) (Amersham Pharmacia Biotech,
Boul Morgan Baie-D’Urfe, Canada). We detected peroxi-
dase activity on X-ray films using an enhanced chemilu-
minescence detection system.
Reverse transcription-PCR
Using the One Step RT-PCR kit (Qiagen), we extracted
total RNA using Trizol reagent and subjected it to
reverse transcription-PCR (RT-PCR). PCR conditions
were 95°C for 30 s, 55 to 58-60°C for 30 s, and 72°C for
1 min through a total of 30 cycles.
The PCR primer sequences for uPA were 5’-TCAC-
CACCAAAATGCTGTGT-3’ (sense) and 5’-AGGC-
CATTCTCTTCCTTGGT-3’(antisense). The primers for
COX2 were 5’-GCAATAACGTGAAGGGCTGT-3’
(sense) and 5’-CGGGAAGAACTTGCATTGAT-3’ (anti-
sense). For glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), the primers used were 5’-ACCACAGTCCAT
GCCATCAC-3’ (sense) and 5’-TCCACCACCCTGT
TGCTGTA-3’ (antisense).
siRNA transfection of COX2/CK2a
For our transfection analyses, 10
6 cells from each bladder
cancer cell line were seeded in 6-cm dish plates and trans-
fected either with 100 nmol/L of control siRNA (Santa
Cruz Biotech., CA, USA) or with the siRNA of COX2,
CK2a. Transfections were carried out using the Lipofecta-
mine system (Invitrogen, CA, USA) in accordance with
the manufacturer’sp r o t o c o l .C O X 2 ,C K 2 a siRNA
duplexes, generated with 3’-dTdT overhangs and prepared
by Qiagen, were chosen against the DNA target sequences
as follows: 5’-AACACCGGATTTTTGACAAG-3’ for
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TCCATTGAAGCTGAAATGGTA-3’for CK2a (cocktail).
Analysis of uPA activity
uPA activity in culture media was analyzed using an
uPA activity assay kit (Chemicon International, Billerica,
MA, USA). In accordance to the manufacture’s protocol,
culture media were collected after indicated treatments
or siRNA transfection. Media were concentrated by cen-
trifugation, samples were added into 96-well plate
together with positive control, and reacted with several
indicated reagents including chromogenic substrates.
After incubation at 37°C for 30 min, absorbance was
measured on a standard microplate reader at 405 nm.
All experiments were done at least thrice in triplicate.
Cell cycle analysis
We performed cell cycle analysis using propidium iodide
by flow cytometry as previously described [22]. All
experiments were done at least thrice in duplicate.
Orthotropic tumor implantation and intravesical
treatment
Animal experiments were approved by the institutional
animal care and use committee at Nara Medical Univer-
sity. Eight week-old female nude mice were maintained on
a daily 12-h cycle of light and dark and were fed standard
diet and water ad libidum. Orthotropic bladder cancer
exhibiting muscle invasive phenotype was established by
inoculating KU7/GFP cells (5 × 10
6) into the mouse blad-
der using transurethral catheter[19]. Seven days after
tumor cell inoculations, mice were randomized into con-
trol (n = 6) or meloxicam (n = 6), treatment groups.
Before the beginning of treatment with meloxicam, we
captured in vivo images of tumor masses in the urinary
bladder, and identified tumor implantation there were no
significant differences of fluorescence intensities between
control and drug treatment groups. Meloxicam was fed in
the drinking water (3.0 mg/l). Mice were sacrificed 25 d
after treatment and bladders were removed, splayed open
on filter paper and fixed in 10% neutral buffered formalin.
Tumor burden was determined by analyzing images of
GFP fluorescence from tumor cells on flat formalin-fixed
bladders captured using a macro-imaging station consist-
ing of a SBIG cooled CCD camera model ST-7XME
(Santa Barbara Imaging Group Inc., Santa Barbara, CA,
USA) mounted onto a dark box. Bladders were embedded
in paraffin, step-sectioned, stained with hematoxylin and
eosin (H&E) for histological evaluation. Invasion depth
means the length from the top to the bottom level of the
largest tumor. Results from animal experiments were com-
piled from data generated from three independent experi-
ments. RNA and protein extractions were performed as
follows: Tumor masses expressing GFP was removed
under the stereoscopic fluorescence microscopy and the
tumors were fragmented by shaver. RNA was extracted by
TriReagent (Ambion, Austin, Texas, USA) according to
the manufacturers’ instructions. Protein was extracted
after homogenization using lysis buffer.
Image analysis
A method for the quantification of tumor burden by
computer assisted image analysis has been described
elsewhere [19]. Briefly, image analysis was performed
with ImageJ public domain software available through
the National Institutes of Health (Bethesda, MD; avail-
able at http://rsb.info.nih.gov/ij/). All images were spa-
tially calibrated for area measurements. Signal strength
was recorded as electrons emitted per second of expo-
sure. The area under the curve (AUC) was determined
from plot profiles based on fluorescent signal strength
and distribution in each individual bladder.
Cell viability assay (MTS assay)
After incubation with the indicated reagents, MTS [(3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulphonyl)-2H-tetrazolium, inner salt] reagent (Pro-
mega, Tokyo, Japan) was added and optical absorbance
at 490 nm was measured using a microplate reader. Cell
viability was expressed as mean percentages the stan-
dard deviations of absorbance before and after treatment
with various reagents. All experiments were performed
in triplicate.
Tissue samples and immunohistochemistry
We obtained specimens of human urinary bladder can-
cers diagnosed as urothelial carcinomas (n = 93) from
patients undergoing transurethral resection or radical
cystectomy, without previous radiation or chemotherapy,
at Nara Medical University Hospital. Clinicopathologic
data of the present cases were reviewed by two urologi-
cal pathologists (K.S. and N.K., department of Pathology,
Nara Medical University Hospital) and summarized in
Table 1. The current research was approved by institu-
tional research board of Nara Medical University and
Table 1 Characterization of urothelial carcinomas
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the collection of specimens, as appropriate, and tumor
stage and grade were noted at the time of diagnosis. We
followed the same tissue fixation and processing proce-
dure as described in a previous report[21,22]. After
deparaffinization, sections were heated for 5 minutes in
10 mM of sodium citrate buffer (pH 6.0) in a pressure
cooker. The sections were then incubated overnight at
4°C with the indicated antibodies. The reactions were
visualized using a Histofine SAB-PO kit and diamino-
benzidine as the chromogen (Nichirei, Tokyo, Japan)
with hematoxylin counterstaining. Percentages of cells
positive for CK2a, COX2 or phosphorylated form of
Akt were expressed per 1,000 cells examined.
Statistical analysis
Data were statistically analyzed using the Student t test
or, for nonparametric analysis, the Kruskal-Wallis test
[23]. Results were considered significant if P < 0.05.
Results
Inhibition of COX2 suppressed growth of urothelial
carcinoma cells
COX2 inhibitors, DuP-697 and CAY10404 at more than
25 μM significantly suppressed viability of human
urothelial carcinoma cell line, UMUC2 expressing wild
type COX2 as assessed by MTS assay (Figure 1(A)).
COX2 activities in cancer cell lines were strongly inhib-
ited by these treatments (data not shown). COX2 gene
silencing by siRNA transfection exhibited the same
effects (Figure 1(B)). Flow cytometry analysis showed
both COX2 inhibitors treatment and COX2 knockdown
induced cell cycle arrest at G1 phase. From western
blotting, p27 was found to be induced in response to
COX2 gene silencing (Figure 1(D)), but other molecules
associated with cell cycle arrest including p53, p21, p16
or Rb protein were not significantly modified (data not
shown).
COX2-dependent activation of casein kinase/uPA signal in
urothelial carcinoma cells
Recently, plasminogen activator systems have been
shown to play important roles in the development of
urinary tumors[24]. Therefore, we examined whether
urokinase or tissue type of the plasminogen activator
was regulated by COX2 in urothelial carcinoma cells.
Figure 2A clearly demonstrated that mRNA expression
and activity of uPA were down-regulated in response to
COX2 knockdown (Figure 2A). In addition, we found
that COX2 contributes to the expression of CK2a,a n
Figure 1 COX2 inhibition or the gene silencing induced cell cycle arrest and cell growth suppression. (A) UMUC2 cells were treated by
the selective COX2 inhibitor, CAY10404(CAY) or DuP-697(DuP) at the indicated concentrations for 48 h, then cell viability was assessed by MTS
assay. (B) At 72 h after transfection of control or COX2 siRNA at 100 nM, cell viability and COX2/COX1 expression were analyzed by MTS assay
and western blotting, respectively. Actin was used for internal positive control. (C) and (D) UMUC2 cells were transfected by control or COX2
siRNA, or treated by DMSO, CAY or DUP, then cell cycle analysis was performed by flow cytometry and p27 expression was examined by
western blotting. Dimethyl sulfoxide was used as control reagent.
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induced by silencing the CK2a gene as well as COX2
(Figures 2B,C and 2D).
COX2 affects CK2a-mediated activation of Akt in
urothelial carcinoma cells
Since activation of phosphoinositol 3 kinase-Akt signal
is one of the upstream targets of plasminogen activator
systems, we investigated association of COX2-CK2a
pathway to Akt. In this experiment, we used a doxorubi-
cin resistant clone derived from a human urothelial car-
cinoma cell line, UMUC6 that we have already
constructed by long term culture using the medium
including doxorubicin at the sub-lethal dose. Akt was
found to be constitutively activated in the UMUC6
resistant (UMUC6R) clone (Figure 3A). Both COX2 and
CK2a knockdowns inhibited Akt activation, but its base-
line expression was not significantly changed (Figure
3B). Reduced uPA activity and cell cycle arrest at G1
phase through p27 induction was mediated by Akt inhi-
bitor treatment as well as COX2 or CK2a gene silencing
in UMUC6R cells (Figure 3C).
COX2 inhibitor suppressed COX2- CK2a-Akt-uPA signal
independent of COX2
Tumor suppression by COX2 inhibitors without affect-
ing COX2 expression or activity has attracted
considerable attention lately. The human urothelial car-
cinoma cell line, UMUC3 lacks the COX2 gene, COX2
inhibitors, CAY10404 and DuP-697 significantly sup-
pressed cancer cell growth in a dose dependent manner
through the induction of cell cycle arrest at G1 phase
(Figure 3A and 3B). Expression of CK2a and phos-
phorylated Akt was down-regulated by COX2 inhibitors
and knockdown of CK2 (Figure 4C). Interestingly, uPA
activity was reduced by COX2 inhibitors, and p21 was
induced in response to COX2 inhibitors treatment or
CK2a gene silencing in addition to p27.
In vivo growth of urothelial carcinoma is suppressed by
COX2 inhibitor, Meloxicam through affecting CK2a-Akt-
p27 signals
KU-7 cells stably expressing the GFP encoding vector
were inoculated into the urinary bladder using a trans-
urethral catheter (Day0). Seven days after inoculation,
we determined grafting to the bladder wall by a fluores-
cence imaging technique and mice were randomized
into a control (n = 6) or meloxicam (n = 6), treatment
groups. Meloxicam fed in the drinking water (3.0 mg/l)
and mice were sacrificed 25days after treatment. As
shown in Figures 5A and 5B, in vivo and ex vivo images
showed meloxicam treatment produced a 5-fold
decrease in tumor area. Invasion depth from the top to
bottom of implanted tumor foci was strongly reduced
Figure 2 CK2a and uPA are downstream of COX2 in UMUC2 cells. (A), (B) and (D) UMUC2 cells were transfected by control or siRNA of
COX2 or CK2a. After 72 h-incubation, mRNA and protein of COX2/COX1, uPA or CK2a were examined by RT-PCR and western blotting. Activity
of uPA in culture media was assessed. Cell viability was analyzed by MTS assay. (C) Cell cycle analysis was performed by flow cytometry.
Dimethyl sulfoxide was used as control reagent.
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data, in the treatment group, mRNA of uPA and protein
levels of CK2a or phosphorylated form of Akt were sig-
nificantly reduced, in contrast, p27 was up-regulated. In
KU-7-GFP cells, seldom expression of COX2 was
observed and it was slightly up-regulated after meloxi-
cam treatment in vivo probably due to a feedback effect.
COX2, CK2a and activated Akt are over expressed in
human urothelial carcinoma of the urinary bladder
Finally, immunohistochemical analysis of COX2, CK2a
or phosphorylated Akt was performed. We examined
surgical specimens consisting of low-grade/noninvasive,
high-grade/invasive, and carcinoma in situ (CIS), all of
which were diagnosed by two urologic pathologists (K.S.
and N.K.). As shown in Figure 6, the percentages of
immunopositive cells for COX2 or activated Akt were
much higher in high-grade urothelial carcinomas,
including CIS, with both minimal (pT1) and wide inva-
sion (≧pT2) than in low-grade (G1 and G2) lesions with
a noninvasive phenotype (pTa). Immunohistochemical
results of CK2a showed an almost similar tendency, but
no significant difference of percentages was not
observed between non-invasive (pTa) and minimal inva-
sive (pT1) tumors (Figure 6 left upper panel). In normal
urothelium obtained from autopsy sample, we found no
or seldom expression of COX2, casein kinase 2a and
activated Akt (data not shown). Taken together, over
expression of COX2, CK2a a n dp h o s p h o r y l a t e dA k ti s
closely associated with bladder cancer progression but
more in vitro experiments are required to know whether
these markers are direct targets to turn less invasive
cancer to a more invasive phenotype.
Discussion
We demonstrated here for the first time that CK2a-mei-
dated uPA signal through phosphorylated Akt is depen-
dent on COX2 and plays an important role in cell
survival of human urothelial carcinoma cells. To date, a
number of reports have been accumulated as to the
Figure 3 COX2 regulates Akt activation through CK2a in UMUC6R cells. (A) UMUC6R cells were obtained from parental line, UMUC6 by
long-term incubation under media including doxorubicin. Phosphorylated Akt and Akt were examined by western blotting. (B), (C) and (D)
UMUC6R cells were transfected by control siRNA or the indicated siRNA of COX2 or CK2a. After 72 h-incubation, expressions of the indicated
gene were examined. Activity of uPA in culture media at 72 h after transfection of control siRNA or siRNA, or at 48 h after treatment with DMSO
or specific inhibitor of Akt, LY294002 at 10 μM (for 30 min) was assessed. Cell cycle analysis was performed by flow cytometry. Dimethyl
sulfoxide was used as control reagent.
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ment, but to our knowledge, no investigations have
pointed out the importance of CK2a as a downstream
molecule. Manna et al. demonstrated the compound 5-
(4-methoxyarylimino)-2-N-(3,4-dichlorophenyl)-3-oxo-
1,2,4-thiadiazolidine (P(3)-25), which is known to pos-
sess anti-bacterial, anti-fungal, anti-tubercular, and local
anesthetic activities, reduced phosphorylation of p65 by
inhibiting upstream kinases including protein kinase A,
CK2a etc resulting in down-regulation of nuclear factor
(NF) kappaB-dependent reporter gene, COX2 in cancer
cells with constitutive expression of NF kappaB[25]. Our
current data indicated reduced expression of CK2a fol-
lowing COX2 inhibitor or the gene silencing, but phos-
phorylation of p65 was not observed (data not shown).
Whether COX2 interacts with CK2a through NF kap-
paB-dependent or independent pathway should be esti-
mated using malignant cells. The present study provided
COX2/CK2a is an upstream of Akt phosphorylation in
urothelial carcinoma cells.C K 2h a sb e e np r e v i o u s l y
reported to increase association of Akt to the Heat
shock protein (HSP) 90 which maintains stability of
phosphorylated Akt at threonine 308 or serine 473 by
inhibiting dephosphorylation by protein phosphatase2A
[26,27]. Because expression of Akt was not affected by
knockdown of COX2 or CK2a,C K 2 a-meditaed stability
of Akt-HSP90 might be a main mechanism by which
COX2 is closely related to Akt phosphorylation at
threonine 308 in urothelial carcinomas. COX2 is fully
expressed, but Akt is not constitutively activated, in
UMUC2 cells, but it can be activated in response to spe-
cific external stimuli (data not shown), therefore, COX2/
CK2a may not directly activate Akt but contributes to
the maintenance of Akt once phosphorylated. COX2/
CK2a and uPA signal actually functioned even in
UMUC2 cells lacking activated Akt, therefore, CK2a is
able to mediate uPA induction independent of Akt. The
interesting data was that COX2 inhibitors down-
Figure 4 Activation of CK2a-uPA signal independent of COX2 in urothelial carcinoma cells. (A) UMUC3 cells lack COX2 gene were treated
by selective COX2 inhibitor, CAY10404(CAY) or DuP-697(DuP) at the indicated concentrations for 48 h, then cell viability was assessed by MTS
assay. (B) Cells were treated by DMSO, CAY or DuP at 25 μM for 48 h, and then Cell cycle analysis was performed by flow cytometry. (C) and (D)
At 48 h after the same treatments (plus LY294002 treatment) or at 72 h after transfection of control or CK2a siRNA, protein expression (COX2,
CK2a, phosphorylated Akt, Akt, p27 or p21) and activity of uPA were examined. Dimethyl sulfoxide was used as control reagent.
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noma cells lacking the COX2 gene. Moreover, it is
epoch-making that COX2 inhibitor can be used for
bladder cancer therapy regardless of COX2 status at
least in the cases with functional CK2a-Akt-uPA, even
though it should be determined whether all COX2 inhi-
bitors have the same pharmacological action. IC50
values of CAY10404 and DuP-649 for COX1 are 500
μMa n d9μM, respectively. Therefore, there are any
possibilities that COX1 contributes to activation of
casein kinase 2 alpha as well as COX2 in UMUC3 cells.
Previous studies showed the importance of phosphatidyl
inositol 3 kinase and Akt pathway in urothelial carci-
noma[28,29], but there are no clinically available inhibi-
tors of this pathway. Possibly we can substitute COX2
inhibitors in bladder cancer treatment. To make sure we
examined the effects of COX2 inhibitors on cell survival
in other cell lines used in the current study than
UMUC2 and UMUC3. The results showed both
CAY10404 and DuP-649 similarly suppressed cell survi-
val of KU-7, UMUC6 and UMUC6R cells at the concen-
trations more than 25 μM (data not shown).
W ef o u n dt h a tt h eC O X 2a n dC K 2 a-Akt-uPA signal
actually function in vivo using the orthotropic implan-
tation animal model. Oral feeding of COX2 inhibitor
could dramatically reduced expression of CK2a,p h o s -
phorylated Akt and uPA, resulting in reduction of
tumor growth and invasiveness. Unfortunately we have
no data to explain the mechanism by which COX2
protein expression in KU7 cells implanted in the urin-
ary bladder was increased in response to treatment
with meloxicam. But this reaction is probably due to
feedback regulation by inhibition of enzymatic activity
of COX2, or due to execution of unidentified mole-
cules or signals by COX2 inhibitors, resulting in tran-
scriptional activation or protein stabilization. It should
Figure 5 COX2 inhibitor suppressed tumor growth through down-regulating CK2a-Akt and uPA signals in vivo. (A) and (B) KU-7-GFP
(constitutively over expression of GFP) cells were transplanted into the urinary bladder of nude mice. At 7 days after inoculation, mice were
randomized into a control (n = 6), meloxicam (n = 6), treatment groups. COX2 inhibitor, meloxicam was fed (3.0 mg/l). Mice were sacrificed 25
days after treatment; tumor size was quantitatively analyzed by using in vivo and ex vivo imaging. (C) mRNA or protein were extracted from the
tumor samples and expression of COX2, phosphorylated Akt, Akt, CK2a, p27 or uPA was examined by western blotting or RT-PCR (left panel).
Invasion depth from the top to bottom of implanted tumor foci was measured (right panel).
Shimada et al. BMC Urology 2011, 11:8
http://www.biomedcentral.com/1471-2490/11/8
Page 8 of 11be further evaluated. Pathological analysis using human
bladder cancer specimens clearly indicated that the
COX2-CK2a and Akt phosphorylation axis is amplified
in human urothelial carcinoma cells, particularly in
advanced cases. These results mean that COX2 expres-
sion and Akt activation change urothelial carcinoma
cells from non-invasive to an invasive phenotype. In
addition to COX2/phosphorylated Akt, CK2a induc-
tion is essential for the progression to high grade and
muscle invasive cancer. In urothelial carcinomas with
microinvasion, CK2a signal does not function but Akt
is activated, suggesting that Akt can be phosphorylated
even in the absence of CK2a, but it is necessary for its
sustainable activation and cancer development. We
cannot explain why CK2a was not detectable in pT1
tumors, even though COX2 was expressed. Positivity
and intensity of COX2 protein did not differ between
tumors of pT1 and more than pT2, therefore, COX2
expression level is not essential. There is the possibility
that the activity of COX2 or its products, including
eicosanoids, might affect the transcription or stabiliza-
tion of CK2a.E x p r e s s i o no fC O X 2 ,C K 2 a or phos-
phorylated Akt in dysplasia was similar to that in high
grade carcinoma in situ (n = 12, intensities of CK2a,
COX2 and phosphorylated Akt were 2.2 ± 0.08, 2.0 ±
0.10 and 2.3 ± 0.07, respectively.). Urothelial dysplasia
is preclinical cancer and low grade intraepithelial neo-
plasia, but its malignant potential is almost similar to
high grade cancer from immunoprofiles of COX2,
CK2a a n dp h o s p h o r y l a t e dA k t .C K 2 a and phosphory-
lated Akt signal might be useful targets for human
bladder cancer treatment. The pathological significance
of COX2 or Akt phophorylation has been well investi-
gated independently[10,29,30], and the current study
opened the window for the problem, ‘how these factors
interact for each other’. COX2 affects Akt activation
through manipulating CK2a expression, which is
mainly involved in bladder cancer development.
Figure 6 Immunohistochemical analysis of COX2, CK2a and phosphorylated Akt in human bladder cancer. Expression of COX2, CK2a or
phosphorylated Akt was immunohistochemically analyzed. Positive percentages were calculated were classified into four intensities (0, less than
10%; 1, 10-30%; 2, 30-50%; 3, more than 50%). The mean of intensity levels in each stage (pTa, pT1, more than pT2 or CIS (pTis)), or in low or
high grade tumor were indicated. Statistical differences of percentages of immunopositive cells between non-invasive/low grade cancer and
invasive/high grade phenotype (* p < 0.05, **p < 0.01).
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Page 9 of 11Conclusions
There are COX2-depdent and -independent mechanisms
by which CK2a-phosphorylated Akt and uPA signal is
activated, resulting in advancement of human bladder
cancer. COX2 inhibitors can shut down not only COX2
but also CK2a level in this signal and bring more effec-
tive therapeutic outcome (Figure 7).
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